Everything below concerns glucagon receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-12. Numbers and descriptions here follow the published literature rather than marketing material.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (solid) | -20 °C or below | Freezer storage with desiccant |
| Solubility | Soluble in water and aqueous buffer | Careful dissolution needed at higher concentrations |
| Appearance | White to off-white lyophilised powder | Visual inspection for discolouration |
| Primary analytical method | Reversed-phase HPLC with UV detection | Paired with mass spectrometry for identity |
| Common synonyms | Triple-agonist peptide; GLP-1/GIP/glucagon agonist | Naming varies across the literature |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
=== Plant extracts === Most or all plants produce chemical insecticides to stop insects eating them. Extracts and purified chemicals from thousands of plants have been shown to be insecticidal, however only a few are used in agriculture. In the USA 13 are registered for use, in the EU 6. In Korea, where it is easier to register botanical pesticides, 38 are used. Most used are neem oil, chenopodium, pyrethrins, and azadirachtin. Many botanical insecticides used in past decades (e.g. rotenone, nicotine, ryanodine) have been banned because of their toxicity.
=== Legal status === In August 2026, Scholar Rock Netherlands withdrew its application for a marketing authorization of Isembyld for the treatment of 5q spinal muscular atrophy. The company stated that the manufacturing site used to make the medicine had not demonstrated compliance with EU GMP requirements within the required time limit. Apitegromab was authorized for medical use in the United States in September 2026. The US Food and Drug Administration (FDA) granted the application for apitegromab fast track, orphan drug, and rare pediatric disease designations. The FDA granted the approval of Isembyld to Scholar Rock.
== Research == Sandra Pizzarello's research over the last forty years involved the analysis of organic compounds in several carbonaceous chondrites, particularly molecular, chiral, and isotopic characterization of amino acids. Because the formation of these organic-rich meteorites pre-date the origin of life, they had been under investigation as potential sites of primal organic compounds which could shed light on abiogenesis, specifically the origin of biological homochirality. Such studies, however, had been inconclusive until 1997 when Cronin and Pizzarello detected 7-9% L-enantiomeric excesses of three abiological amino acids while analyzing the Murchison meteorite. Given Earth's history of meteoric impacts and the observation that meteors contain an excess of the biologically relevant L-stereoisomer of certain amino acids, Pizzarello studied the effect of meteoritic amino acids in enantiomeric excess on the formation of other biological molecules. In one study, Pizzarello found that nonracemic solutions of abiological isovaline and proteinogenic alanine can direct the condensation of glycolaldehyde to produce nonracemic solutions of threose and erythrose via an aldol reaction concluding that amino acids can act as asymmetric catalysts in carbohydrate synthesis. These findings support the origin of life hypothesis that homochirality originated prior to life and from extraterrestrial origins. However, Pizzarello's theoretical inquiries into cosmochemical evolution remain debated based on suspect analytical evidence of meteoritic enantiomeric excesses.
== Mechanism == A CI experiment involves the use of gas phase acid-base reactions in the chamber. Some common reagent gases include: methane, ammonia, water and isobutane. Inside the ion source, the reagent gas is present in large excess compared to the analyte. Electrons entering the source will mainly ionize the reagent gas because it is in large excess compared to the analyte. The primary reagent ions then undergo secondary ion/molecule reactions (as below) to produce more stable reagent ions which ultimately collide and react with the lower concentration analyte molecules to form product ions. The collisions between reagent ions and analyte molecules occur at close to thermal energies, so that the energy available to fragment the analyte ions is limited to the exothermicity of the ion-molecule reaction. For a proton transfer reaction, this is just the difference in proton affinity between the neutral reagent molecule and the neutral analyte molecule. This results in significantly less fragmentation than does 70 eV electron ionization (EI). The following reactions are possible with methane as the reagent gas.
Sources: en.wikipedia.org
1993/1063) A43 Trunk Road (Silverstone Bypass) (Detrunking) Order 1993 (S.I. 1993/1064) North Norfolk Action (Miscellaneous Provisions) Order 1993 (S.I. 1993/1065) Gipsy Encampments (Metropolitan District of Sefton) Order 1993 (S.I. 1993/1066) Airports Slot Allocation Regulations 1993 (S.I. 1993/1067) Oldham National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1068) Cornwall and Isles of Scilly Mental Handicap National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/1069) Merchant Shipping (Vessels in Commercial Use for Sport or Pleasure) Regulations 1993 (S.I. 1993/1072) Aviation Security (Air Cargo Agents) Regulations 1993 (S.I. 1993/1073) Vocational Training (Public Financial Assistance and Disentitlement to Tax Relief) (Amendment) Regulations 1993 (S.I. 1993/1074) Plymouth Development Corporation (Planning Functions) Order 1993 (S.I. 1993/1075) Social Security (Consequential Provisions) (Northern Ireland) Act 1992 Appointed Day Order 1993 (S.I. 1993/1079) Vocational Training (Tax Relief) (Amendment) Regulations 1993 (S.I. 1993/1082) Peak Rail Light Railway Order 1993 (S.I. 1993/1083) Dacorum and St Albans Community National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1084) Rochdale Healthcare National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1085) Horizon National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1086) Bexley and Greenwich (London Borough Boundaries) Order 1993 (S.I. 1993/1091) Insurance Companies (Cancellation No.
Biological activities of metal ion-binding compounds can be changed in response to the increment of the metal concentration, and based on the latter compounds can be classified as "metal ionophores", "metal chelators" or "metal shuttles". If the biological effect is augmented by increasing the metal concentration, it is classified as a "metal ionophore". If the biological effect is decreased or reversed by increasing the metal concentration, it is classified as a "metal chelator". If the biological effect is not affected by increasing the metal concentration, and the compound-metal complex enters the cell, it is classified as a "metal shuttle". The term ionophore (from Greek ion carrier or ion bearer) was proposed by Berton Pressman in 1967 when he and his colleagues were investigating the antibiotic mechanisms of valinomycin and nigericin. Many ionophores are produced naturally by a variety of microbes, fungi and plants, and act as a defense against competing or pathogenic species. Multiple synthetic membrane-spanning ionophores have also been synthesized. The two broad classifications of ionophores synthesized by microorganisms are:
Polysaccharide peptide (PSP) is a protein-bound polysaccharide extracted from the edible mushroom Coriolus versicolor. PSP is currently in the animal-testing phase of research in many countries for use as an anti-tumor drug. It appears to work as a biological response modifier (BRM), enhancing the body's own use of macrophages and T-lymphocytes, rather than directly attacking any tumors. Polysaccharide krestin (PSK) was first isolated in Japan in the late 1960s while PSP was isolated about 1983 in China. Each compound has shown remarkable anticancer properties with few side effects. By 1987 PSK accounted for more than 25% of total national expenditure for anticancer agents in Japan.
Portugal's African colonial expansion culminated in the 1890 British Ultimatum, which thwarted its ambitions. The ultimatum and the 1891 Anglo-Portuguese Treaty, compounded by existing turmoil, led to political erosion and weakened the monarchy.
=== Pests and predators === Liliaceae are subject to a wide variety of diseases and pests, including insects, such as thrips, aphids, beetles and flies. Also fungi, viruses and vertebrate animals such as mice and deer. An important horticultural and garden pest is the scarlet lily beetle (Japanese red lily beetle, Lilioceris lilii) and other Lilioceris species which attack Fritillaria and Lilium. Lilium species may be food plants for the Cosmia trapezina moth. A major pest of Tulips is the fungus, Botrytis tulipae. Both Lilium and Tulipa are susceptible to a group of five viruses of the family Potyviridae, specifically the potyvirus (named for potato virus Y) group, which includes the tulip-breaking virus (TBV) and the lily streak virus (lily mottle virus, LMoV) resulting in 'breaking' of the color of the flowers. The viruses are transmitted by aphids. This breaking effect was of economic importance during the tulip mania of the seventeenth century, because it appeared to be producing new varieties. In modern times tulip breeders have produced varieties that mimic the effect of the virus, without being infected. One of these varieties is known as 'Rembrandt', after the Dutch artist of that name. Contemporary tulip owners commonly had Rembrandt and other artists paint their flowers to preserve them for posterity, hence the 'broken' tulips were known as Rembrandt tulips at that time. Another modern variety is 'Princess Irene'. One of the tulip breaking viruses is also named the Rembrandt tulip-breaking virus (ReTBV).
Sources: en.wikipedia.org
== Production == The series is a continuation of the series John Mulaney Presents: Everybody's in LA which ran for six episodes on Netflix as part of the Netflix is a Joke Festival in 2024. That series received both the Critics' Choice Television Award and the Television Critics Association for Outstanding Talk Series, as well as the Primetime Emmy Award for Outstanding Picture Editing for Variety Programming. The name of the series was changed from Everybody's in LA due to reactions from focus groups which showed that "people in the United States don't like Los Angeles". The show would consist of 12 episodes from March 12 to May 28, 2025, with Mulaney returning as host and Richard Kind continuing his role as side-kick and announcer. Prior to the show's premiere, Deadline Hollywood reported in January 2025 that the show was given a two-season order.
Moreover, the Court of Justice has clarified that its recognition of rights was 'inspired' by member states' own 'constitutional traditions', and international treaties. These include rights found in member state constitutions, bills of rights, foundational Acts of Parliament, landmark court cases, the European Convention on Human Rights, the European Social Charter 1961, the Universal Declaration of Human Rights 1948, or the International Labour Organization's Conventions. The EU itself must accede to the ECHR, although in Opinion 2/13 the Court of Justice delayed, because of perceived difficulties in retaining an appropriate balance of competences.
In his post-election victory speech, Lula adopted a more moderate tone, saying that he intends to "pacify the country". Though he later, indirectly, called his political opponent Jair Bolsonaro authoritarian and fascist, by saying that he had "defeated authoritarianism and fascism in Brazil". This was considered to be a repeat of previous rhetoric from during the election campaign, when Lula frequently compared his rival to leaders of the military dictatorship and the fascist regimes of Italy and Germany, as well calling Bolsonaro a "plague of locusts". He was inaugurated on 1 January 2023. That day Lula and Geraldo Alckmin were sworn in as president and vice-president of Brazil, respectively, for the period 1 January 2023 – 4 January 2027.
=== Preclinical === AM-510 – undefined mechanism of action – opioid-related disorders ATI-1013 – monoclonal antibody against nicotine – smoking withdrawal CTRX-1001 – immunostimulant – opioid-related disorders CTRX-2001 – immunostimulant – opioid-related disorders Cyclobenzaprine (KRL-102; TNX-102; Tonmya; VLD-cyclobenzaprine) – tricyclic antidepressant (various actions) – alcoholism Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (various actions) and prazosin (α1-adrenergic receptor antagonist) – cocaine-related disorders Dimethyltryptamine (DMT; EBRX-101) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – alcoholism EQL-101 – undefined mechanism of action (non-hallucinogenic non-cardiotoxic ibogaine derivative) – substance use disorders Flumazenil/naloxone transdermal patch (MX-1607; RescuePatch) – combination of flumazenil (GABAA receptor negative allosteric modulator/benzodiazepine antagonist) and naloxone (opioid receptor antagonist) – substance-related disorders GM-3009 – κ-opioid receptor agonist (noribogaine analogue) – opioid-related disorders INDV-1000 (GABAB PAM) – GABAB receptor positive allosteric modulator – substance-related disorders KB-128 – serotonin 5-HT2C receptor G protein-biased agonist, serotonin 5-HT2A and 5-HT2B receptor antagonist – alcoholism LPH-48 – undefined mechanism of action and serotonergic psychedelic ((shorter-acting LPH-5 analogue) – alcoholism M-101 – GABA receptor antagonist – substance-related disorders 5-Methoxy-2-aminoindane (MEAI; 5-MeO-AI; CMND-100) – serotonin–norepinephrine releasing agent – cocaine-related disorders Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABAA receptor positive allosteric modulator) – substance-related disorders Midomafetamine microneedle transdermal patch (MDMA; ecstasy) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, entactogen – substance-related disorders Naltrexone controlled-release (BICX101, BICX-101) – opioid receptor antagonist – alcoholism, opioid-related disorders Nicotine degrading enzyme (ATI-3009; NicA2; NicA2-J1) – enzyme – smoking withdrawal PPL-138 (BU10038, BU-10038) – nociceptin receptor agonist, μ-opioid receptor agonist, opioid peptide agonist – alcoholism, cocaine-related disorders PSIL-001 (DMT analogue) – non-hallucinogenic serotonin 5-HT1 receptor modulator – substance-related disorders PSIL-002 (DMT analogue) – non-hallucinogenic serotonin 5-HT1 receptor modulator – substance-related disorders Psilacetin (O-acetylpsilocin; 4-AcO-DMT) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, serotonergic psychedelic – substance-related disorders Pudafensine (IP-2015; IP-2017; IPNP-2015; IPTN-2021) – serotonin–norepinephrine–dopamine reuptake inhibitor – substance-related disorders Research programme: psychedelic-based neurological therapeutics - Psilera – undefined mechanism of action and serotonergic psychedelics – alcoholism Research programme: psychoplastogen therapeutics - Collaborations Pharmaceuticals – undefined mechanism of action – opioid-related disorders SVN-015 – serotonin–dopamine reuptake inhibitor – substance-related disorders SXC-2023 – cystine–glutamate antiporter (SLC7A11; System xc- or Sxc) activator – cocaine-related disorders, smoking withdrawal [15] [16] TACT411 – serotonin 5-HT1B receptor modulator and monoamine transporter modulator – alcoholism TACT523 – undefined mechanism of action – alcoholism TACT833 – serotonin 5-HT1B receptor modulator and monoamine transporter modulator – alcoholism VS-01 (VS-01-HAC) – ammonia scavenger – substance-related disorders
Sources: en.wikipedia.org
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.
Cool, dry conditions with desiccant are standard for the solid form. Long-term storage is usually at freezer temperatures, with short-term handling at refrigerator temperature. Vials are allowed to equilibrate before opening to prevent condensation.
Lipid conjugation increases hydrophobicity, which shifts chromatographic retention and can broaden peaks. It also creates additional related species when acylation is incomplete or the chain is oxidised. Methods are therefore developed to separate acylated and non-acylated forms explicitly.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.